Sign in
Taking people in United StatesPhase 1

Tests how fasting and pausing GLP-1 medicines affect stomach contents in people with obesity

Studies how fasting and pausing GLP-1 medicines affect food left in the stomach.

Key facts

Who runs it
Novo Nordisk A/S
Where
Cypress, United StatesSee the site
Trial code
Registry title
Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)
Status
Recruiting
Phase
Phase 1
People taking part
71 people, planned
Started
7 Nov 2025
Expected to end
6 Jan 2027
Type of study
Interventional, 3 groups
Treatments tested
  • Liraglutide
  • Oral Semaglutide
  • Semaglutide
Record updated
21 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with overweight or obesity, with or without type 2 diabetes. It studies how fasting and pausing GLP-1 medicines change food left in the stomach.

Age
18 years or older
Sex
Men and women
Disease stage
BMI between 25.0 and 45 kg/m^2, with the extra weight due to body fat. Type 2 diabetes is allowed if diagnosed more than 180 days before screening.
Earlier treatment
People with type 2 diabetes must take no diabetes medicines, or a stable dose of metformin for at least 90 days before screening. Insulin or insulin secretagogues are not allowed.
Biomarker or test result
HbA1c must be 6.5 % (48 mmol/mol) or lower without type 2 diabetes, and below 10.5 % (91 mmol/mol) with type 2 diabetes.

Main reasons for not taking part

  • Significant stomach or bowel disorders that may affect absorption of drugs or food
  • Past major surgery on the oesophagus or stomach, such as gastric bypass or sleeve gastrectomy
  • Gastroparesis, hiatal hernia or severe reflux
  • Other medicines that affect how the stomach moves
  • Cannot lie on the right side for the stomach ultrasound

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Male or female
  • Age 18 years or above at the time of signing the informed consent
  • BMI between 25.0 and 45 kilogram per meter square (kg/m\^2) (both inclusive) at screening. Overweight should be due to excess adipose tissue, as judged by the investigator; For participants with T2D:
  • Diagnosed with type 2 diabetes (T2D) more than (>) 180 days before screening
  • Treatment with:; no antidiabetic drugs or; stable metformin dose or both [stable dose is defined as the maximum daily tolerated dose for more than or equal to (≥) 90 days before screening]

Who cannot take part

  • Use of other medications known to affect the motility of the stomach
  • Current treatment with insulin or insulin secretagogues that might increase risk of hypoglycaemia during periods of fasting
  • Recurrent severe hypoglycaemia (more than 1 severe hypoglycaemic event within 180 days) or hypoglycaemic unawareness as judged by the investigator or hospitalisation for diabetic ketoacidosis within 180 days before screening
  • Presence of clinically significant gastrointestinal disorders or symptoms of gastrointestinal disorders potentially affecting absorption of drugs or nutrients, or as judged by the investigator
  • History of major surgical procedures involving the oesophagus or stomach potentially affecting absorption of trial products (e.g. subtotal and total gastrectomy, sleeve gastrectomy, gastric bypass surgery) or current presence of gastrointestinal implant
  • Diagnosed with or suspected to suffer from clinically significant gastroparesis, hiatal hernia or severe gastro-oesophageal reflux diseases with daily symptoms and/or in supine position
  • Glycosylated hemoglobin (HbA1c) > 6.5 percent (%) 48 millimole per mole (mmol/mol) at screening; For participants with T2D:
  • HbA1c ≥ 10.5 % (91 mmol/mol) at screening
  • Inability to lie in the right lateral decubitus position for gastric ultrasonography
  • Unusual meal habits and special diet requirements or unwillingness to eat the meals provided in the study; For participants without T2D:

Where in United States

  • Altasciences Clinical LA, Inc.Cypress, United StatesContact: Novo NordiskTaking people

About the trial

What the trial wants to find out

The purpose of this study is to investigate how the duration of fasting and temporary stopping of Glucagon-Like-Peptide 1 (GLP-1) medications affect the amount of food left in the stomach in people using liraglutide (injected), semaglutide (taken by mouth) or semaglutide (injected). The length of participants participation in the study will depend on the type of GLP-1 RA treatment participants are already using.

The 3 groups in the trial

  • LiraglutideTreatment being tested

    Participants will receive liraglutide subcutaneously.

  • Oral semaglutideTreatment being tested

    Participants will receive semaglutide orally.

  • SemaglutideTreatment being tested

    Participants will receive semaglutide subcutaneously.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Investigation of the Effect of Fasting Duration and Temporary Withholding of GLP-1 RAs on Retained Gastric Contents in Participants Treated With s.c. Liraglutide, Oral Semaglutide or s.c. Semaglutide
Plain-language title
Tests how fasting and pausing GLP-1 medicines affect stomach contents in people with obesityGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
21 July 2026